PDF herunterladen
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2016; 52(03): 144-154
DOI: 10.1055/s-0040-1712616
Original Article

Cervical Cancer – Bench to Bedside

T. Rajkumar
1   Prof. and Head, Dept. of Molecular Oncology, Cancer Institute (WIA), Adyar, Chennai.
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

Cervical cancer is the second most common cancer in Indian women and 4th most common cancer in women world-wide. Over nearly two decades, we have carried out epidemiological and molecular studies in cervical cancer, with an intent to identify potential early diagnostic biomarkers, predictive and prognostic markers, develop newer therapies against cervical cancer and identify potential new targets for therapy.

Our studies had identified 14 high risk and 10 low risk human papilloma virus (HPV) in our cervical cancer patients for the first time; had identified life style related cofactors in the development of cervical cancer (paan chewing, parity, early age at first sexual intercourse and first childbirth, husband with two or more sexual partners). We have developed a p16 ELISA kit for cervical cancer screening for use at point of care like PHC's; identified a 7 gene signature which help identify patients who can be treated with radiotherapy alone; identified potential prognostic markers for use in the clinic; developed the country's first Dendritic cell vaccine therapy for cervical cancer and completed the phase 1 study; have identified newer potential therapeutic targets for treatment of cervical cancer.

Keywords

Cervical cancer - Human papilloma virus - p16 ELISA - Predictive and Prognostic markers - UBE2C - Dendritic Cell Vaccine for treatment

DR. R.V. RAJAM ORATION delivered during NAMSCON 2015 at the All India Institute of Medical Sciences, Patna.




Publikationsverlauf

Artikel online veröffentlicht:
09. Mai 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Ferlay J, Soerjomataram I, Ervik M, et al. (2013). GLOBOCAN 2012 v 1 . 0 , C an cer I n cid en ce an d Mortality Worldwide: IARC Cancer Base No. 11 (Internet). Available from: http://globocan.iarc.fr.
  • 2 Zur Hausen H (2009) . Papillomaviruses in the causation of human cancer – a brief historical account. Virology 384: 260-265.
  • 3 Arends MJ, Buckley CH, Wells M (1998). Aetiology, pathogenesis and pathology of cervical neoplasia. J Clin Pathol 51: 96-103.
  • 4 Franceschi S , Rajkumar T, Vaccarella S, et al. (2003). Human papilloma virus and risk factors for cervical cancer in Chennai, India: A case control study. Int J Cancer 107: 127-133.
  • 5 Rajkumar T, Franceschi S , Vaccarella S, et al. (2003). The role of paan chewing and dietary habits in cervical carcinoma in Chennai, India. Br J Cancer 88: 1388-1393.
  • 6 International Collaboration of Epidemiological Studies of Cervical cancer (2006). Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 119:1108-1124.
  • 7 International Collaboration of Epidemiological Studies of Cervical cancer (2006). Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 118:1481-1495.
  • 8 International Collaboration of Epidemiological Studies of Cervical Cancer (2007). Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data on 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370: 1609-1621.
  • 9 International Collaboration of Epidemiological Studies of Cervical Cancer (2009). Cervical carcinoma and sexual behaviour: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiology Biomarkers and Prevention 18: 1060-1069.
  • 10 Franceschi S, Plummer M, Clifford G, et al. (2009). Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer 101:865-870.
  • 11 Rajkumar T , Sabitha K , Vijayalakshmi N, et al. (2011). Identification and validation of g e n e s i n v o l v e d i n c e r v i c a l tumourigenesis. BMC Cancer 11:80.
  • 12 Rajkumar T, Vijayalakshmi N, Sabitha K, et al. (2009). A 7 gene expression score predicts for radiation response in cancer cervix. BMC Cancer 9: 365.
  • 13 Rajkumar T, Sharmila R, Majhi U, Selvaluxmi G, Vasanthan A, Shanta V (1998). Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur J Gynecol Oncol 19: 556-560.
  • 14 Vijayalakshmi N, Selvaluxmi G, Mahji U, Rajkumar T (2002). c- Myc oncoprotein expression and prognosis in patients with carcinoma c e r v i x - A n immunohistochemical study. Eur J Gynecol Oncol 23: 135-138.
  • 15 Bose MV, Gopi setty G , Ganeshrajah S, Rajkumar T (2012). Dominant negative Ubiquitin conjugating enzyme E2C sensitizes cervical cancer cells to radiation. Int J Rad Biol 88: 629-634.
  • 16 Ramanathan P, Ganeshrajah S, Raghanvan RK , Singh SS , Rajkumar T (2014). Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer-a feasibility study. Asian Pacific J Cancer Prev 15: 5909-5916.